Insider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Sells 5,025 Shares of Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director David B. Roberts sold 5,025 shares of the stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $75.62, for a total value of $379,990.50. Following the transaction, the director now directly owns 14,114 shares of the company’s stock, valued at $1,067,300.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

LeMaitre Vascular Stock Down 1.2 %

Shares of NASDAQ LMAT traded down $0.90 during midday trading on Wednesday, reaching $75.00. 109,442 shares of the company’s stock traded hands, compared to its average volume of 122,731. The company has a market cap of $1.68 billion, a price-to-earnings ratio of 49.67, a P/E/G ratio of 2.99 and a beta of 0.88. The stock’s 50 day simple moving average is $66.47 and its 200-day simple moving average is $59.23. LeMaitre Vascular, Inc. has a one year low of $44.27 and a one year high of $76.24.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.05. The company had revenue of $53.48 million for the quarter, compared to analyst estimates of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.27 EPS. Equities analysts predict that LeMaitre Vascular, Inc. will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date of this dividend is Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio is presently 42.38%.

Wall Street Analyst Weigh In

LMAT has been the subject of a number of research reports. Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and increased their target price for the company from $59.00 to $75.00 in a research report on Friday, April 26th. StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. JMP Securities upped their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research report on Friday, May 3rd. Barrington Research lifted their target price on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Finally, KeyCorp assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, February 6th. They issued a “sector weight” rating on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and a consensus price target of $73.83.

Institutional Investors Weigh In On LeMaitre Vascular

Several hedge funds have recently added to or reduced their stakes in LMAT. BluePath Capital Management LLC purchased a new position in shares of LeMaitre Vascular in the 3rd quarter valued at about $31,000. YHB Investment Advisors Inc. acquired a new position in shares of LeMaitre Vascular during the 1st quarter worth approximately $36,000. DekaBank Deutsche Girozentrale purchased a new position in shares of LeMaitre Vascular during the 3rd quarter valued at approximately $38,000. SRS Capital Advisors Inc. grew its stake in LeMaitre Vascular by 325.5% in the 4th quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 524 shares during the period. Finally, Envestnet Portfolio Solutions Inc. purchased a new stake in LeMaitre Vascular in the 1st quarter worth $206,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.